Comments
LONDON According to the Cambridge English Dictionary, an economy is “the system of trade and industry by which the wealth of a country is made and used.” For the last few centuries, this system has been dominated by the paradigm of capitalism, in which the private owners of capital, and not the state, control the trade of goods and services.
The slave trade and plantation economy of the early colonial period in America were among the original manifestations of this economic paradigm, as the European propertied classes asserted their newfound power over dwindling tributary systems and the interim feudal arrangements were replaced with John Locke’s quasi-religious notions of private property, which would come to conquer Western economic theory for the next three hundred years.
This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
A top healthcare VC predicted microbiome drugs would rebound in 2021 as part of Business Insider s year-end roundup of healthcare predictions.
Though the biotech industry s infatuation with the promise of the bacteria in our gut dates back years, research failures and the 2019 uBiome scandal previously chilled investors interests.
More established microbiome companies have continued the search to prove the microbiome can bear fruit for patients and investors alike.
Seres Therapeutics, currently valued at $2.4 billion, is the space s clear frontrunner, having announced success last August in a late-stage study for one of its microbiome drug candidates.
Venrock’s Bryan Roberts on the firm’s new $450 million fund, and where it’s shopping in 2021
Venrock, the 51-year-old firm that started as the venture arm of the Rockefeller family, has closed its ninth fund with $450 million, the same amount it raised for its last two funds. The outfit, with offices in Palo Alto, New York and Cambridge, clearly feels comfortable with the fund size, but it says change is otherwise a constant, given that trends and tech shift so fast that so-called pattern recognition can prove a liability if an investment team isn’t careful.
To learn more about what the team is tracking at Venrock whose newest exits include last year’s IPOs of Cloudflare and 10x Genomics IPO, and the recent sales of Corvidia and Personal Capital we were in touch earlier today with longtime partner Bryan Roberts, who has spent his 24-year career in venture with the firm.
This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
We asked healthcare and biotech venture capitalists from leading firms like Venrock and NEA to share their predictions for 2021.
2020 was a pivotal year for healthcare, shaped by the pandemic and a booming IPO market for digital health companies.
In 2021, VCs are anticipating a rough time for young startups, a big year for digital health IPOs, and increased attention for startups looking to address the healthcare industry s shortcomings.
It s difficult to imagine what 2021 has in store, after a pandemic-ravaged 2020.
But when it comes to the healthcare industry, investors are predicting certain events and trends are bound to transpire in the coming year.